Searle Pakistan Limited has organized a Seminar on the latest approach for controlling Blood Pressure, his topic of presentation was “Vasodilating Beta-Blockers The New Frontier” at a local hotel in Karachi; it was one of the seminars of Continuous Medical Education (CME) program of the organization for increasing scientific awareness among the medical community for better patient management.
Prof. Azhar Masood Farooqi, an icon in the field of Cardiology and
Former Executive Director,
National Institute of Cardiovascular Diseases was the chief guest at the
occasion while Prof. Khan Shah Zaman, Executive Director, National Institute of
Cardiovascular Diseases was the chair of the seminar and Prof. M. Z. Jilani
Consultant Physician & Cardiologist, Ziauddin Medical University Karachi
was the key speaker of the seminar. More than 150 Doctors participated in the
interactive session from different institutes and areas of Karachi in that CME
activity.
The program was started with the recitation of Holy Quran and I commenced the session as
moderator and formally introduced and invited guests on stage to chair the
Seminar.
While introducing the academicians, I shared the success story of Searle Pakistan Limited
to become among the top ten companies of Pakistan and known among the
healthcare community because of its quality products, efficacy and affordable
price.
Formally
seminar was commenced with a short speech of Deputy Managing Director Mr.
Hassan Tariq, he shared briefly about the services of Searle Pakistan for the
people of Pakistan and shares the concept of “Business with social
responsibility”. He assured the participants that Searle will provide quality
Products for healthcare community to overcome the misery of ailing humanity. He
thanked Prof. Azhar Masood Farooqi, an icon in the field of Cardiology as a
chief guest, Prof. Khan Shah Zaman, Executive Director, National Institute of
Cardiovascular Diseases and Prof. M. Z. Jilani Consultant Physician &
Cardiologist, Ziauddin Medical University for their precious time for Byscard
seminar, and also thanked participants for their kind efforts and trust which
they conferred on Searle Pakistan.
Now Prof. M. Z. Jilani invited
for his presentation on Hypertension, in which he discussed the prevalence and global
cardiovascular disease mortality and incidence of Hypertension in America,
Europe and third world countries and finally in Pakistan. Secondly he shared
the stages of hypertension, cardiovascular disease risk factors and consequences
of Hypertension in end organ damage with their dangerous
outcomes.
Nebivolol is the 3rd Generation new innovative Cardio-selective β-Blocker which provides even better Blood Pressure reduction in comparison with all other conventional β-blockers without β-Blocker like side effects.’
- Nebivolol Approved by FDA and ESC in hypertension and heart failure.
- Nebivolol has unique mode of action.
- Nebivolol has the highest B1-receptor affinity among Beta-blockers and has potent vasodilatory effects to improve endothelial function.
- Nebivolol once daily treatment significantly reduces systolic and diastolic blood pressure in patients.
- Nebivolol Provides improvement in erectile function in hypertensive patients compared with other B-blockers.
- Nebivolol Well tolerated with proven efficacy in heart failure.
- Reduction in all cause mortality/CV hospitalization.
- Nebivolol can lead to 1/3 reduction in the risk of ischemic events.
Prof. Azhar Masood Farooqi and Prof. Khan Shah Zaman concluded the session with the remarks that Nebivolol is remarkable and safest option in order to treat the cardiovascular disorders. He emphasized on doctors to use effective drug therapy to minimize the fatal risks and to enhance the quality of patients’ life.
